821 The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.